Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Anthracyclines, like doxorubicin, are effective anti-cancer drugs but cause severe cardiotoxicity, limiting their use.
• Exosomes are natural nanocarriers with biocompatibility and homing properties, offering potential for targeted drug delivery.
• Tumor exosomes can be engineered as drug carriers to enhance tumor cell uptake and reduce systemic toxicity.

Purpose of the Study:

• To develop a novel drug delivery system using chitosan-modified tumor exosomes for doxorubicin.
• To evaluate the efficacy of this system in reducing doxorubicin-induced cardiotoxicity.
• To assess the anti-tumor effectiveness and safety profile of the modified exosomes.

Main Methods:

• Doxorubicin was loaded into tumor exosomes, and the exosome surface was modified with chitosan.
• In vitro cell experiments were conducted to assess cytotoxicity and cellular uptake.
• In vivo pharmacokinetic studies and an ectopic nude mouse tumor model were used to evaluate therapeutic efficacy and cardiotoxicity.

Main Results:

• Chitosan-modified tumor exosomes demonstrated enhanced stability and drug loading.
• The modified exosomes significantly reduced doxorubicin-induced cardiotoxicity in vivo.
• Remarkable anti-tumor efficacy was observed with the chitosan-exosome system, with reduced systemic side effects.

Conclusions:

• Chitosan-modified tumor exosomes represent a promising nanocarrier for doxorubicin delivery, effectively mitigating cardiotoxicity.
• This approach offers a viable strategy to improve the therapeutic index of anthracycline chemotherapeutics.
• The study highlights a novel and effective nanomedicine platform for cancer treatment with reduced adverse effects.